Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

107.79 

1.32 1.2%

as of Jul 06 '20

52 Week Range:

62.48 110.25


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve acute and chronic GVHD, as well as Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC); and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome, as well as a pivotal program for solid tumors with driver activations of FGF/FGFR. Further, it is involved in developing INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Additionally, the company develops Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Syros Pharmaceuticals, Inc.; and Innovent Biologics, Inc., as well as BriaCell Therapeutics Corp. for treating cancer. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Equity (BVPS) -0.86
-0.71
-1.43
-1.31
0.18
-0.52
0.48
1.96
8.32
8.45
11.21
growth rate 0.0% 0.0% 0.0% 100.0% -100.0% 100.0% 308.3% 324.5% 1.6% 32.7%
Earnings BIT -211.87
-31.85
-186.54
-44.15
-82.85
-4.80
50.65
164.00
-224.03
154.87
421.12
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 223.8% -100.0% 100.0% 171.9%
Avg.PE -2.30
-51.60
-10.60
-56.50
-6.35
-6.35
2,423.33
223.13
-146.81
165.00
46.34
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -90.8% -100.0% 100.0% -71.9%
ROA -44.85
-5.30
-45.58
-13.44
-17.32
-6.64
0.71
7.88
-15.89
4.43
14.72
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 1,009.9% -100.0% 100.0% 232.3%
ROE 206.90
35.90
82.10
25.30
14.59
35.29
-30.55
6.16
19.76
growth rate -82.7% 128.7% -69.2% -16.8% 141.9% -100.0% 100.0% 220.8%
ROIC 6.07
14.77
-23.38
6.14
19.42
growth rate 143.3% -100.0% 100.0% 216.3%
Cur. Ratio 4.94
4.01
2.29
2.27
5.14
3.16
5.01
3.63
4.01
4.31
4.83
growth rate -18.8% -42.9% -0.9% 126.4% -38.5% 58.5% -27.5% 10.5% 7.5% 12.1%
Quick Ratio 4.77
3.79
2.09
2.20
5.04
2.97
4.89
3.50
3.83
4.11
4.73
growth rate -20.6% -44.9% 5.3% 129.1% -41.1% 64.7% -28.4% 9.4% 7.3% 15.1%
Leverage 5.89
3.91
1.41
1.37
1.32
growth rate -33.6% -63.9% -2.8% -3.7%
Balance Sheet Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Acct.Receivable 163.70
5.70
6.42
70.95
36.27
57.93
114.45
148.76
266.30
307.60
308.81
growth rate -96.5% 12.5% 1,006.0% -48.9% 59.7% 97.6% 30.0% 79.0% 15.5% 0.4%
Acct.Payable 66.31
70.00
95.15
24.46
30.09
75.60
67.67
103.83
83.65
growth rate 5.6% 35.9% -74.3% 23.0% 151.3% -10.5% 53.4% -19.4%
Cur.Assets 656.10
455.50
310.78
309.51
555.80
679.57
842.38
994.18
1,504.85
1,832.25
2,481.49
growth rate -30.6% -31.8% -0.4% 79.6% 22.3% 24.0% 18.0% 51.4% 21.8% 35.4%
Total Assets 712.40
489.60
328.96
330.42
629.57
796.48
1,007.44
1,638.60
2,302.58
2,645.76
3,426.75
growth rate -31.3% -32.8% 0.4% 90.5% 26.5% 26.5% 62.7% 40.5% 14.9% 29.5%
Cash 449.80
417.90
292.46
224.06
471.93
452.30
521.44
652.34
899.51
1,163.98
1,832.68
growth rate -7.1% -30.0% -23.4% 110.6% -4.2% 15.3% 25.1% 37.9% 29.4% 57.5%
Inventory 0.00
0.00
0.00
0.28
0.41
0.36
1.78
4.11
6.48
6.97
11.40
growth rate 46.0% -11.8% 398.0% 130.3% 57.9% 7.5% 63.6%
Cur.Liabilities 132.80
113.60
135.61
136.07
108.04
221.06
168.01
273.50
375.40
425.28
513.34
growth rate -14.5% 19.4% 0.3% -20.6% 104.6% -24.0% 62.8% 37.3% 13.3% 20.7%
Liabilities 814.80
578.20
556.04
505.38
822.68
878.11
836.29
1,219.13
671.95
719.80
828.34
growth rate -29.0% -3.8% -9.1% 62.8% 6.7% -4.8% 45.8% -44.9% 7.1% 15.1%
LT Debt 443.10
293.40
316.15
331.08
661.57
589.98
619.89
651.48
16.61
17.43
growth rate -33.8% 7.8% 4.7% 99.8% -10.8% 5.1% 5.1% -97.5% 5.0%
Equity -102.38
-88.64
-227.08
-174.96
-81.63
171.16
419.47
1,630.63
1,925.97
2,598.41
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% 145.1% 288.7% 18.1% 34.9%
Common Shares 103.00
122.00
125.00
130.00
148.00
168.00
187.00
194.00
205.00
216.00
218.00
growth rate 18.5% 2.5% 4.0% 13.9% 13.5% 11.3% 3.7% 5.7% 5.4% 0.9%
Cash Flow Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Capital Expenditures 0.39
4.11
3.80
2.84
4.27
27.88
26.00
120.28
111.02
73.48
78.06
growth rate 953.9% -7.6% -25.3% 50.3% 553.3% -6.7% 362.6% -7.7% -33.8% 6.2%
Cash Dividends 0.00 0.00 0.00 0.00
growth rate
Cash From OA 12.40
97.90
-161.72
0.00
9.18
26.26
89.41
304.76
-92.99
336.23
710.66
growth rate 689.5% -100.0% 0.0% 186.0% 240.5% 240.9% -100.0% 100.0% 111.4%
FCF per Share 0.12
0.77
-0.80
-0.75
-0.03
-0.33
0.21
0.85
-0.05
0.42
2.71
growth rate 541.7% -100.0% 0.0% 0.0% 0.0% 100.0% 304.8% -100.0% 100.0% 545.2%
Sale Purchase of Stock 19.47
47.71
73.16
92.84
86.44
49.97
716.15
growth rate 145.1% 53.3% 26.9% -6.9% -42.2% 1,333.1%
FCF 12.00
94.00
-166.00
-98.00
5.00
-2.00
61.00
184.00
-204.00
263.00
633.00
growth rate 683.3% -100.0% 0.0% 100.0% -100.0% 100.0% 201.6% -100.0% 100.0% 140.7%
Income Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Sales 9.30
169.90
94.46
297.06
354.95
511.50
753.75
1,105.72
1,536.22
1,881.88
2,158.76
growth rate 1,726.9% -44.4% 214.5% 19.5% 44.1% 47.4% 46.7% 38.9% 22.5% 14.7%
Op.Income -139.80
14.00
-186.54
-44.32
-83.15
-4.80
50.65
164.00
-224.03
154.87
421.12
growth rate 100.0% -100.0% 0.0% 0.0% 0.0% 100.0% 223.8% -100.0% 100.0% 171.9%
IBT 0.00
-31.80
-186.54
-44.15
-82.85
-48.55
7.56
107.40
-312.29
115.35
486.79
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% 1,321.4% -100.0% 100.0% 322.0%
Net Income -211.90
-31.80
-186.54
-44.32
-83.15
-48.48
6.53
104.22
-313.14
109.49
446.91
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 1,495.8% -100.0% 100.0% 308.2%
EPS -2.06
-0.26
-1.49
-0.34
-0.56
-0.29
0.03
0.54
-1.53
0.51
2.05
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 1,700.0% -100.0% 100.0% 302.0%
Gross Profit 9.30
169.90
94.46
296.90
354.32
160.97
247.27
465.67
142.60
589.80
890.40
growth rate 1,726.9% -44.4% 214.3% 19.3% -54.6% 53.6% 88.3% -69.4% 313.6% 51.0%
R&D 119.40
123.90
178.71
210.39
260.44
347.52
479.51
581.86
1,326.36
growth rate 3.8% 44.2% 17.7% 23.8% 33.4% 38.0% 21.3% 128.0%

Quarterly Statements

Item Name Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Earnings BIT 80.61
105.09
137.45
97.99
-657.61
growth rate 30.4% 30.8% -28.7% -100.0%
Balance Sheet Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Acct.Receivable 244.08
302.68
276.12
308.81
351.52
growth rate 24.0% -8.8% 11.8% 13.8%
Acct.Payable 70.36
66.18
95.38
83.65
60.94
growth rate -5.9% 44.1% -12.3% -27.2%
Cur.Assets 1,904.50
2,058.63
2,319.60
2,481.49
1,716.17
growth rate 8.1% 12.7% 7.0% -30.8%
Total Assets 2,754.16
2,947.63
3,214.82
3,426.75
2,752.42
growth rate 7.0% 9.1% 6.6% -19.7%
Cash 1,299.70
1,416.22
1,702.02
1,832.68
1,043.24
growth rate 9.0% 20.2% 7.7% -43.1%
Inventory 7.13
6.53
7.37
11.40
13.98
growth rate -8.4% 12.8% 54.8% 22.6%
Cur.Liabilities 364.52
367.11
461.68
513.34
503.41
growth rate 0.7% 25.8% 11.2% -1.9%
Liabilities 668.59
700.44
792.29
828.34
814.70
growth rate 4.8% 13.1% 4.6% -1.7%
LT Debt 17.65
17.86
18.08
growth rate 1.2% 1.2%
Equity 2,085.57
2,247.19
2,422.53
2,598.41
1,937.72
growth rate 7.8% 7.8% 7.3% -25.4%
Common Shares 0.21
0.22
0.22
0.22
0.22
growth rate 0.5% 0.0% 0.5% 0.5%
Cash Flow Statement Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Capital Expenditures 18.27
47.29
-16.81
29.32
39.27
growth rate 158.9% -100.0% 100.0% 33.9%
Cash Dividends
growth rate
Cash From OA 155.66
152.96
270.42
131.62
-683.42
growth rate -1.7% 76.8% -51.3% -100.0%
Sale Purchase of Stock
growth rate
FCF 137.40
105.67
253.60
102.30
-722.68
growth rate -23.1% 140.0% -59.7% -100.0%
Income Statement Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Sales 497.86
529.93
551.58
579.39
568.51
growth rate 6.4% 4.1% 5.0% -1.9%
Op.Income 80.61
105.09
137.45
97.99
-657.61
growth rate 30.4% 30.8% -28.7% -100.0%
IBT 104.10
108.67
148.02
126.00
-704.08
growth rate 4.4% 36.2% -14.9% -100.0%
Net Income 102.31
105.32
128.27
111.01
-720.64
growth rate 2.9% 21.8% -13.5% -100.0%
EPS
growth rate
Gross Profit 204.72
211.16
240.21
234.31
-546.23
growth rate 3.2% 13.8% -2.5% -100.0%
R&D
growth rate

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A (91.44)

YOY Growth Grade:

C (53.64)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 46.34 57.61 28.24
EPS / Growth 0.0% 1.87 31.1%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 27.0% 38.4%
Future PE 0.00 42.88 50.49
Future EPS 1.87 20.47 48.38
Value Price
MOS %
0.00
-100.0%
216.98
101.3%
603.80
460.2%
MOS Price 0.00 108.49 301.90
IRT 57.61 10.78 8.68

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.